Quick comparison
| Peptide | Class | Evidence | Status |
|---|---|---|---|
| DSIP | Nonapeptide | Moderate | Not FDA-approved; research/compounding use only, prescription required |
| CJC-1295 / Ipamorelin Stack | GHRH analog + ghrelin receptor agonist stack | Limited | Not FDA-approved for sleep, compounding-pharmacy access only |
| Selank | Heptapeptide (tuftsin derivative) | Limited | Not FDA-approved, Russian prescription anxiolytic only |
| Epitalon | Synthetic tetrapeptide | Limited | Not FDA-approved, research/compounding legal status shifting |
The ranking
DSIP
DSIP, or Delta Sleep-Inducing Peptide, is a nonapeptide first isolated from rabbit cerebral venous blood in the 1970s and later studied as a possible sleep aid.
It holds the top spot here because it is the only peptide in this category with a published double-blind, matched-pairs human clinical trial (n=16) that named sleep latency and sleep efficiency as direct, measured outcomes rather than an inferred benefit.
That same trial found the effect on chronic insomniacs was weak and possibly confounded, and subjective sleep quality did not improve, so the ranking reflects “most directly studied,” not “most proven effective.” An earlier, smaller human crossover study (n=6) reported a much larger effect on total sleep time, but DSIP’s gene, protein, and receptor have never been isolated in humans, leaving its underlying mechanism unresolved.
Strengths
- Only peptide with a named, direct sleep-latency/efficiency endpoint in a human double-blind RCT
- Some human data (small crossover study) reporting increased total sleep time versus placebo
- Long research history dating to the 1970s, giving more accumulated (if dated) human data than most alternatives
Limitations
- The highest-authority trial itself concluded DSIP is "not likely to be of major therapeutic benefit" for chronic insomnia
- No confirmed human receptor or isolated gene/protein; mechanism is still debated by researchers
- Existing trials are small (n=6 to n=16), decades old, and used IV dosing rather than the subcutaneous routes used in current practice
- Best for
- Chronic insomnia research where sleep latency is the target
- Evidence
- Moderate
- Status
- Not FDA-approved; research/compounding use only, prescription required
CJC-1295 / Ipamorelin Stack
This stack pairs CJC-1295, a modified GHRH analog, with Ipamorelin, a ghrelin receptor (GHS-R1a) agonist, to encourage the body’s largest natural growth hormone pulse, which normally occurs during the first slow-wave sleep episode after sleep onset.
Human research (Raun et al., 1998) shows Ipamorelin triggers pulsatile GH release without significantly raising cortisol, ACTH, or prolactin, and a human trial of CJC-1295 (Teichman et al., 2006, n=65 healthy adults) documented large, sustained GH and IGF-1 increases.
Critically, that CJC-1295 trial did not measure sleep as an endpoint at all, so the sleep benefit here is inferred from GHRH-SWS coupling rather than directly demonstrated.
It ranks highly because the mechanistic and hormonal evidence is unusually well cited compared to most sleep peptides, even though no controlled trial has tested this stack against a sleep outcome.
Strengths
- Human data (Raun et al., 1998) shows Ipamorelin raises GH without spiking cortisol, ACTH, or prolactin
- Human trial (Teichman et al., 2006) confirms strong, reproducible GH/IGF-1 elevation from CJC-1295
- Mechanistic rationale (GHRH-driven slow-wave sleep coupling) is well documented in the broader literature
Limitations
- No trial has measured sleep itself as an outcome for this stack
- Sleep benefit is inferred/mechanistic, not directly tested in humans
- With-DAC CJC-1295 causes sustained 24-hour GH elevation and is not considered appropriate for sleep-timed use
- Best for
- Sleep architecture support via nightly GH pulse timing
- Evidence
- Limited
- Status
- Not FDA-approved for sleep, compounding-pharmacy access only
Selank
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and approved in Russia since 2009 as a prescription anxiolytic.
Its proposed mechanism is allosteric modulation of the GABA-A receptor, producing a benzodiazepine-like effect without occupying the benzodiazepine binding site, alongside effects on BDNF and inhibition of enkephalin degradation (mechanism study (Kolomin et al. 2018)).
It is ranked third here because the anxiolytic mechanism is relatively well characterized and plausibly supports sleep onset in anxiety-driven insomnia specifically, not insomnia broadly. Critically, sleep was never used as a primary endpoint in Selank’s Russian trials, so any sleep benefit is inferred secondary to anxiety reduction rather than directly demonstrated.
Strengths
- Mechanism (GABA-A modulation) is more clearly defined than several other peptides on this list
- Reported CNS effects within minutes of intranasal use (human observational reports)
- Long-standing regulatory approval history in Russia as an anxiolytic, distinct from unregulated research chemicals
Limitations
- No trial has used sleep as a primary or even measured secondary outcome
- Best suited only to sleep problems where anxiety is the driving cause, not general insomnia
- Evidence base originates almost entirely from Russian research groups, without independent Western replication
- Best for
- Insomnia driven by anxiety rather than direct sleep onset failure
- Evidence
- Limited
- Status
- Not FDA-approved, Russian prescription anxiolytic only
Epitalon
Epitalon (Epithalon) is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modeled on epithalamin, a bovine pineal extract, developed by Vladimir Khavinson’s group in St. Petersburg.
It ranks here because its proposed mechanism, restoring the nocturnal melatonin peak in aging pineal tissue, has been shown in animal studies (aged rhesus monkeys) and human observational work from the same lab, giving it a real mechanistic story tied to circadian sleep regulation rather than sedation.
It is not ranked higher because that evidence base comes almost entirely from one Russian research group and has not been independently replicated in Western studies, and the outcome actually measured was melatonin rhythm, not sleep architecture or sleep quality directly.
Strengths
- Plausible mechanism: normalizes nocturnal melatonin peak per animal and human observational data from Khavinson's group
- Also studied for telomere elongation via telomerase activation, a related but distinct longevity claim
Limitations
- Evidence comes from a single lab group, with no independent Western replication
- Studies measured melatonin rhythm, not sleep architecture or subjective sleep quality
- Not evaluated in controlled trials against a direct sleep endpoint
- Best for
- Circadian and age-related melatonin decline, not acute insomnia
- Evidence
- Limited
- Status
- Not FDA-approved, research/compounding legal status shifting
How we picked
Each peptide was assessed on the strength of human evidence for sleep specifically, whether sleep was a directly measured outcome or an inferred one, and its current safety and regulatory standing.
DSIP is the only compound with a direct double-blind RCT measuring sleep latency and efficiency, while the others rely on mechanistic plausibility or outcomes like hormone levels or melatonin rhythm rather than sleep itself.
This ranking is not an endorsement: none of these peptides are FDA-approved for sleep or insomnia, evidence quality varies widely, and the order reflects evidence strength per use case, not a recommendation to use any of them.
Important safety note
These compounds are largely available only through compounding pharmacies or research-chemical channels, and human safety data is limited, dated, or drawn from small trials in some cases. Anyone considering peptide therapy for sleep should involve a qualified clinician who can evaluate individual health history and current regulatory status, since availability is actively shifting. This overview does not constitute medical advice and includes no dosing guidance.
Frequently asked questions
Which peptide actually has clinical proof it improves sleep?
DSIP is the only one tested in a direct double-blind RCT with sleep latency and efficiency as named outcomes, but the same trial concluded it's "not likely to be of major therapeutic benefit" for chronic insomnia. Other studies on DSIP show conflicting results.
Is the CJC-1295/Ipamorelin stack proven to help sleep?
No trial has measured sleep as an endpoint for this stack. The rationale rests on the well-documented link between growth hormone pulses and slow-wave sleep onset, but that's a mechanistic inference, not direct evidence.
Does Selank work like a sleeping pill?
No. Selank has a documented GABA-A and anxiolytic mechanism from Russian research, but its trials never used sleep as a primary endpoint. It's better understood as addressing anxiety that disrupts sleep, not inducing sleep directly.
Is Epitalon's sleep benefit backed by independent research?
Not yet. Epitalon's evidence comes from one research group (Khavinson's lab) and measured restoration of nocturnal melatonin rhythm, not sleep architecture itself. It hasn't been independently replicated in Western studies.
Are any of these peptides FDA-approved for sleep?
No. None of the four peptides in this ranking are FDA-approved for sleep or insomnia. Availability, legal status, and regulatory categorization are also actively changing.
Can these peptides be combined or stacked?
The research reviewed here doesn't provide controlled data on combining these specific peptides for sleep outcomes. Any stacking decision should involve a qualified clinician rather than self-directed experimentation.
Why do these rankings all say "limited" or "moderate" instead of "strong"?
Because no peptide in this category has robust, replicated human evidence with sleep as the primary measured outcome. Even DSIP, the most direct case, produced weak and inconsistent results across the studies that exist.